THE SENATE
THE THIRTIETH LEGISLATURE
REGULAR SESSION OF 2020
COMMITTEE
ON COMMERCE, CONSUMER PROTECTION, AND HEALTH
Senator Rosalyn H. Baker, Chair
Senator Stanley Chang, Vice-Chair
MEASURES DEFERRED TO FRIDAY, MARCH 13, 2020
DATE:
|
Friday, March 13, 2020
|
TIME:
|
9:30 AM
|
PLACE:
|
Conference Room 229
State Capitol
415 South Beretania Street
|
DECISION MAKING ON THE
FOLLOWING MEASURE(S):
HB1637
HD1
(HSCR912-20)
Status and Testimony
|
RELATING TO HEALTH.
Repeals the ceiling for using moneys in the civil monetary penalty special
fund by DOH for compliance activities approved by the Centers for Medicare
and Medicaid Services. Appropriates funds to DOH for the establishment of a
medicare administrator position. Effective 7/1/2050. (HD1)
|
CPH, WAM
|
HB1659
HD3
(HSCR995-20)
Status and Testimony
|
RELATING TO HEALTH.
Authorizes a pharmacy to provide a customized patient medication package to
any person upon consent, with a valid prescription, and in compliance with
labeling and dispensing requirements. Effective 07/01/2050. (HD3)
|
CPH
|
HB2097
HD2
(HSCR948-20)
Status and Testimony
|
RELATING TO MEDICAL CANNABIS.
Allows for a process to remediate any batch of cannabis or manufactured
cannabis product that fails laboratory testing standards so long as any final
cannabis or manufactured cannabis product passes all the laboratory
standards. Authorizes licensed dispensaries to manufacture and distribute
edible cannabis products, under certain conditions, and circulate, sponsor,
and promote educational and scientific information and events related to
cannabis. Effective 7/1/2050. (HD2)
|
CPH, JDC
|
HB2102
HD1
(HSCR700-20)
Status and Testimony
|
RELATING TO HEMP PRODUCTS.
Requires labels on hemp products. Prohibits unwarranted health-related
statements about hemp products. Establishes standards for hemp product
manufacturers. Prohibits the manufacture or sale of any food into which a
hemp product has been added. Prohibits the sale of hemp products designed to
appeal to children. Establishes that a product shall not be considered
adulterated or misbranded solely by the inclusion of hemp with certain
exceptions. Clarifies that a licensed medical cannabis dispensary is not
prohibited from manufacturing, distributing, or selling products that contain
hemp, or cannabinoids, extracts, or derivatives from hemp, subject to certain
conditions. Prohibits the sale of hemp products to persons under twenty-one
years of age. Requires DOH to report to the legislature. Effective
7/1/2050. Sunsets 6/30/2023. (HD1)
|
CPH, JDC/WAM
|
HB1805
HD1
(HSCR789-20)
Status and Testimony
|
RELATING TO PRESCRIPTION DRUGS.
Requires prescription drug manufacturers to notify prescription drug benefit
plans and pharmacy benefit managers if a proposed increase in the wholesale
acquisition cost of certain drugs would result in a percentage increase of
ten per cent or more than the percentage change in the Consumer Price Index
over a two year period. Requires the drug manufacturer to identify and
report to the insurance commissioner information on certain drugs whose
wholesale acquisition cost increases by a certain amount during a specified
time frame. Effective 7/1/2050. (HD1)
|
CPH
|
HB2340
HD2
(HSCR923-20)
Status and Testimony
|
RELATING TO DEAD BODIES.
Clarifies prohibited actions related to anatomical gifts and disposition of
bodies. Effective 7/1/2050. (HD2)
|
CPH, JDC
|
No testimony will be accepted.
FOR AMENDED NOTICES: Measures that have been deleted are stricken through and
measures that have been added are underscored. If a measure is both
underscored and stricken through, that measure has been deleted from the
agenda.
FOR FURTHER INFORMATION, PLEASE CONTACT THE COMMITTEE CLERK AT 808-586-6070.